BR112023003455A2 - Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas - Google Patents

Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas

Info

Publication number
BR112023003455A2
BR112023003455A2 BR112023003455A BR112023003455A BR112023003455A2 BR 112023003455 A2 BR112023003455 A2 BR 112023003455A2 BR 112023003455 A BR112023003455 A BR 112023003455A BR 112023003455 A BR112023003455 A BR 112023003455A BR 112023003455 A2 BR112023003455 A2 BR 112023003455A2
Authority
BR
Brazil
Prior art keywords
methods
embolization
cholesterol crystals
cyclodextrins
treatment
Prior art date
Application number
BR112023003455A
Other languages
English (en)
Portuguese (pt)
Inventor
Kerwin Diana
Camm Jason
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of BR112023003455A2 publication Critical patent/BR112023003455A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
BR112023003455A 2020-08-27 2021-08-27 Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas BR112023003455A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071222P 2020-08-27 2020-08-27
PCT/US2021/048072 WO2022047241A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
BR112023003455A2 true BR112023003455A2 (pt) 2023-05-02

Family

ID=80353289

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003455A BR112023003455A2 (pt) 2020-08-27 2021-08-27 Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas

Country Status (11)

Country Link
US (1) US20230330133A1 (https=)
EP (1) EP4203972A4 (https=)
JP (1) JP7835735B2 (https=)
KR (1) KR20230096975A (https=)
CN (1) CN116322643A (https=)
AU (1) AU2021333902A1 (https=)
BR (1) BR112023003455A2 (https=)
CA (1) CA3190563A1 (https=)
IL (1) IL300806A (https=)
MX (1) MX2023002419A (https=)
WO (1) WO2022047241A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
AU2022222756A1 (en) * 2021-02-18 2023-09-14 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
CN104244956B (zh) * 2012-04-13 2020-04-17 L&F研究有限公司 使用环糊精的方法

Also Published As

Publication number Publication date
IL300806A (en) 2023-04-01
CA3190563A1 (en) 2022-03-03
EP4203972A1 (en) 2023-07-05
US20230330133A1 (en) 2023-10-19
JP7835735B2 (ja) 2026-03-25
KR20230096975A (ko) 2023-06-30
MX2023002419A (es) 2023-07-11
EP4203972A4 (en) 2024-07-17
WO2022047241A1 (en) 2022-03-03
AU2021333902A1 (en) 2023-03-16
CN116322643A (zh) 2023-06-23
JP2023543133A (ja) 2023-10-13

Similar Documents

Publication Publication Date Title
BR112023003455A2 (pt) Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas
Fillingham et al. Tranexamic acid use in total joint arthroplasty: the clinical practice guidelines endorsed by the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee society
Fuji et al. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin
Zou et al. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty
Mei et al. The efficacy of tranexamic acid for orthognathic surgery: a meta-analysis of randomized controlled trials
Handschin et al. Low molecular weight heparin-induced skin necrosis—a systematic review
BR112022011951A2 (pt) Tratamento de esclerose lateral amiotrófica e distúrbios relacionados
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
Zimmerer et al. Diagnosis and treatment of optic nerve trauma
Kosucu et al. Effects of perioperative magnesium sulfate with controlled hypotension on intraoperative bleeding and postoperative ecchymosis and edema in open rhinoplasty
Sapate et al. To study the effect of injection dexmedetomidine for prevention of pain due to propofol injection and to compare it with injection lignocaine
Tanoğlu et al. Two-stage surgery for the malleolar fracture− dislocation with severe soft tissue injuries does not affect the functional results
Song et al. Effects of remote ischemic preconditioning in patients with concentric myocardial hypertrophy: a randomized, controlled trial with molecular insights
Carpentieri et al. Clinical experience with an oral anticoagulant in children.
BR112023003490A2 (pt) Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas
Ghiasi et al. A pilot study of nebulized heparin for prevention of ventilator induced lung injury: comparative effects with an inhaled corticosteroid
JP5456802B2 (ja) 細胞遊走促進剤及び創傷治療用の経皮吸収剤
Riva et al. Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients
Colwell et al. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery
PH12014000275A1 (en) Antiviral pharmaceutical formulation for the effective treatment of dengue, influenza and hiv/aids
Jawad et al. Effect of intraoperative mitomycin-C application in outcome of external dacryocystorhinostomy
CN103340863A (zh) 烟酰胺在制备治疗糖尿病伤口愈合药物中的应用
BRPI0416706A (pt) composições farmacêuticas para o tratamento da disfunção, doença ou distúrbio renal, em particular em recipientes diabéticos
Amer et al. Intracerebral hemorrhage associated COVID-19 patient with normal coagulation profile after ECMO treatment: A case report
Morawetz et al. Is nebulised hypertonic saline useful as an adjunctive treatment for acute bronchiolitis in infants and children less than 24 months of age?

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]